VLGC Virologic (MM)

ViroLogic Announces Presentations at the 96th Annual Meeting of the American Association for Cancer Research (AACR) SOUTH SAN FRANCISCO, Calif., April 7 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced today that four presentations related to its eTag technology will be made at the 96th Annual Meeting of the American Association for Cancer Research (AACR), taking place April 16-20 in Anaheim, California. Details are as follows: Presentation Time: Monday, April 18, 8:00 am - 12:00 pm Presentation Number: 2309 Cellular Responses to PI3K/AKT and MAPK Pathway Inhibition in Melanoma Presentation Time: Tuesday, April 19, 8:00 am - 12:00 pm Presentation Number: 3688 Correlation of ErbB Activation Status and Clinical Response to Herceptin Treated Breast Cancer Patients Presentation Time: Tuesday, April 19, 1:00 pm - 5:00 pm Presentation Number: 4567 IC50 Determination for Receptor-Targeted Compounds and Downstream Signaling Presentation Time: Wednesday, April 20, 8:00 am - 12:00 pm Presentation Number: 5762 Multiplexed Assay for Assessing ErbB/HER Receptor Pathways in Formalin- fixed and Paraffin-embedded Cancer Cell Lines About the eTag System ViroLogic's eTag assays enable detailed analysis of protein drug targets and signaling pathways in cancer cells, including samples that are formalin-fixed, paraffin-embedded, which is the standard format in most pathology labs. The assays can provide information on a drug's mechanism of action, selectivity and potency in a biological setting in pre-clinical research, and enable enrichment or selection of clinical trial populations later in a drug's development. In addition, ViroLogic believes these assays will be used to help physicians better determine whether certain therapies are more appropriate for individual cancer patients, and whether to combine therapies with different mechanisms or properties. About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.virologic.com/. DATASOURCE: ViroLogic, Inc. CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic, Inc., +1-650-635-1100; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, or , for ViroLogic, Inc. Web site: http://www.virologic.com/

Copyright